Cancer and systemic inflammation: Treat the tumour and treat the host

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1409-1412

  Roxburgh, C S D ^a   McMillan, D C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

anti inflammatory agents; appetite loss; cachexia; depression; fatigue; pain; physical function; systemic inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANOREXIA; BREAST CANCER; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DEPRESSION; DISEASE ASSOCIATION; FATIGUE; HUMAN; INFLAMMATION; LOSS OF APPETITE; LUNG CANCER; MEDICAL DECISION MAKING; NEOPLASM; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WEIGHT REDUCTION;

HUMANS; INFLAMMATION; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84896494532     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.90     Document Type: Review

References (31)

1. Christoffersen T (2013) Cancer, cachexia, prostanoids, and NSAIDs. Acta Oncol 52: 3-5.
2. Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500(1-3): 399-411.
3. Douglas E, McMillan DC (2013) Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score. Cancer Treat Rev; e-pub ahead of print 28 November 2013; doi:10.1016/j.ctrv.2013.11.007.
4. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6): 448-454.
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88(1): 218-230.
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
7. Illi J, Miaskowski C, Cooper B, Levine JD, Dunn L, West C, Dodd M, Dhruva A, Paul SM, Baggott C, Cataldo J, Langford D, Schmidt B, Aouizerat BE (2012) Association between pro-and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine 58: 437-447.
8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 4(12): 977-987.
9. Kacevska M, Robertson GR, Clarke SJ, Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4: 137-149.
10. Kirkova J, Walsh D, Aktas A, Davis MP (2010) Cancer symptom clusters: old concept but new data. Am J Hosp Palliat Care 27: 282-288.
11. Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P (2013a) Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res 19: 5456-5464.
12. Laird BJ, McMillan DC, Fayers P, Fearon K, Kaasa S, Fallon MT, Klepstad P (2013b) The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 18(9): 1050-1055.
13. Laird BJ, Scott AC, Colvin LA, McKeon AL, Murray GD, Fearon KC, Fallon MT (2011) Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage 42: 1-11.
14. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367(17): 1596-1606.
15. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gülich M, Karrefors I, Norli B et al. (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606.
16. MacDonald N (2007) Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 5: 157-162.
17. Madeddu C, Dess̀i M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Maccio A, Mantovani G (2012) Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 31: 176-182.
18. McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67: 257-262.
19. McMillan DC (2013a) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39: 534-540.
20. McMillan DC (2013b) Cancer and systemic inflammation: stage the tumour and stage the host. Br J Cancer 109: 529.
21. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79: 495-500.
22. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson 3rd AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS (2011) Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 103: 1540-1551.
23. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, Morrison DS, McMillan DC (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 103(6): 870-876.
24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
25. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149-163.
26. Saligan LN, Kim HS (2012) A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav Immun 26: 830-848.
27. Solheim TS, Fearon KC, Blum D, Kaasa S (2013a) Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 52: 6-17.
28. Solheim TS, Blum D, Fayers PM, Hjermstad MJ, Stene GB, Strasser F, Kaasa S (2013b) Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod?-analysis from a multicenter cross sectional study. Acta Oncol; e-pub ahead of print 2 September 2013.
29. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363: 733-742.
30. Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC (2012) Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 84: 130-148.
31. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25): 3076-3082.